Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect Achieve Life Sciences to post earnings of ($0.37) per share for the quarter.
Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Achieve Life Sciences Stock Down 4.5 %
NASDAQ ACHV traded down $0.12 during trading on Tuesday, hitting $2.52. 46,194 shares of the company traded hands, compared to its average volume of 187,059. The business has a fifty day simple moving average of $2.56 and a 200 day simple moving average of $3.42. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $5.59. The company has a market capitalization of $87.41 million, a P/E ratio of -2.23 and a beta of 1.49.
Insider Activity at Achieve Life Sciences
In other Achieve Life Sciences news, CFO Mark K. Oki acquired 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $28,900. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.00% of the stock is owned by corporate insiders.
About Achieve Life Sciences
(
Get Free Report)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
Further Reading
Before you consider Achieve Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Achieve Life Sciences wasn't on the list.
While Achieve Life Sciences currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
